News | February 25, 2022
Risk appetite key to innovation in pharma and biopharma
Industry leaders discusses the need of innovation for the Indian drug industry at BioAsia 2022.
Industry leaders discusses the need of innovation for the Indian drug industry at BioAsia 2022.
It is a Phase 3 ready anti-myostatin adnectin for Spinal Muscular Atrophy (SMA).
The first wave of shipments includes several countries, such as Germany, France and Austria
Methodology developed by QIMR Berghofer researchers utilizing the Agilent Cary 630 FTIR
Modi holds a bachelor's degree in Chemical Engineering from University of Cincinnati and a master’s degree in Marketing, Management Strategy and Finance from Northwestern’s Kellogg School of Management
The recently released WHO guideline on hypertension treatment (2021), recommends that patients with stable blood pressure can be asked to visit clinics at 3-6 month intervals as an important strategy to improve hypertension control
Cataract is the most common cause of blindness in India, and that diabetes is to be blamed for the massive number of damaged eyes
Collaboration in the industry needs to be institutionalised to drive the growth.
The drug will be manufactured at the group's formulation manufacturing facility at the SEZ, Ahmedabad
he financing was significantly oversubscribed with high demand from both existing and new investors.
Subscribe To Our Newsletter & Stay Updated
